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IMPORTANCE Depression is associated with increased inflammation, which may precede its 
onset. especially in older people. Some preclinical data suggest potential antidepressant 
effects of aspirin, supported by limited observational data suggesting lower rates of 
depression in individuals treated with aspirin. There currently appears to be no 
evidence-based pharmacotherapies for the primary prevention of depression. 
OBJECTIVE To determine whether low-dose aspirin (100 mg) reduces the risk of depression in 
healthy older adults. 
DESIGN, SETTING, AND PARTICIPANTS This double-blinded, placebo-controlled randomized 
clinical trial was a substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial. 
which examined if aspirin increased healthy life span. defined as survival free of dementia and 
disability. The prespecified secondary outcome was depression. Individuals of all 
races/ethnicities older than 70 years in Australia, as well as white individuals older than 70 
years and black and Hispanic individuals older than 65 years in the United States, were 
included. 
INTERVENTIONS Participants were randomized to aspirin (100 mg daily) or placebo, with a 
median (interquartile range) follow-up of 4.7 (3.5-5.6) years. 
MAIN OUTCOMES AND MEASURES The primary outcome was a proxy measure of major 
depressive disorder defined as a score of 8 or more on the Center for Epidemiologic Studies 
Depression 10-item (CES-D-10) scale. 
RESULTS Of the 19114 participants enrolled in the trial. 9525 received aspirin and 9589 
received a placebo. The mean (SD) age was 75.2 (4.0) years in the aspirin group and 75.1 (4.5) 
years in the placebo group; 9531 (56.4%) were women. Participants' demographics and 
clinical characteristics at baseline were similar between groups. A total of 79 886 annual 
CES-D-10 measurements were taken, with a mean of 4.2 measurements per participant. 
There were no significant differences at annual visits in the proportions of CES-D-10 scores of 
8 or more between the aspirin and placebo groups. The incidence rate of new 
CES-D-10 scores of 8 or more was 70.4 events per 1000 person-years in the aspirin group 
and 69.1 in the placebo group (hazard ratio, 1.02 [95% Cl, 0.96-1.08]; P = .54). 
CONCLUSIONS AND RELEVANCE Low-dose aspirin did not prevent depression in this large-scale 
study of otherwise healthy older adults. 
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El 
P reventive approaches for many noncommunicable dis-orders from cancer to cardiovascular disease have hadmajor influence on incidence, morbidity, and mortal-
ity. Psychiatry, in contrast, lacks an evidence base for population-
wide prevention strategies. Existing effective preventive strat-
egies for depression largely use psychotherapeutic, cognitive
behavioral–type therapies for people with early-stage or emerg-
ing symptoms.1 There are no evidence-based primary preven-
tive pharmacotherapies for depression.
Support for a possible role of inflammation in depression
include the association between inflammatory disorders and
higher rates of depression, the propensity of proinflammatory
cytokines and interferon administered to volunteers to induce
depressive symptoms, and higher levels of the inflammatory
blood biomarkers tumor necrosis factor α, interleukin-6 (IL-
6), and C-reactive protein in depression, including in late-life
depression.2,3 After antidepressant treatment for depression,
IL-4, IL-6, and IL-10 cytokine levels were reduced when symp-
toms were reduced.4 Higher levels of cytokines and acute-
phase markers, such as C-reactive protein, appear to precede the
onset of de novo depression.5 These associations raise the ques-
tion as to whether depression could be prevented by suppress-
ing inflammation. Indeed, preclinical, pharmacoepidemio-
logic, and pilot clinical trial data suggest that aspirin, with its
anti-inflammatory properties, may have clinical potential.6
The Aspirin for the Prevention of Depression (ASPREE-D)
trial7 is a substudy of the Aspirin in Reducing Events in the El-
derly (ASPREE) trial. The parent study was a 5-year random-
ized clinical trial jointly supported by the National Institute
on Aging and the Australian National Health and Medical Re-
search Council comparing the effects of aspirin (100 mg daily)
and placebo in 19 114 healthy older adults on survival free
of dementia or physical disability.8,9 The primary aim of
ASPREE-D was to determine if the use of low-dose aspirin re-
duces the risk of depression in healthy individuals 70 years or
older (or 65 years or older among racial/ethnic minorities in the
US), as assessed using the Center for Epidemiologic Studies De-
pression Scale 10-item (CES-D-10) scores.9 The secondary aims
were to determine its effect on mental health quality of life,
as indexed by the 12-item Short Form Health Survey (SF-12)
mental component summary scores, and assess the time to a
first CES-D-10 score of 8 or more, as well as incidence of hos-
pitalization for depression. The primary hypothesis was that
low-dose aspirin would reduce the risk of depression, de-
fined as a CES-D-10 score of 8 or more, at any postrandomiza-
tion point.
Methods
The ASPREE trial was a multicenter, double-blinded, placebo-
controlled, primary-prevention randomized clinical trial of
daily usage of 100 mg of enteric-coated aspirin among older
adults who were relatively healthy and community dwelling
in Australia and the US and were 70 years and older (or 65 years
or older, if African American or Hispanic and dwelling in the
US). The trial was conducted according to the Australian Na-
tional Statement on Ethical Conduct in Human Research,10 the
Australian Code for the Responsible Conduct of Research,11 the
2008 Declaration of Helsinki,12 and the International Confer-
ence on Harmonization of Good Clinical Practice E613 and was
approved by institutional review boards at all sites. The pro-
tocol was developed in accordance with Standard Protocol
Items Recommendations for Intervention Trials (SPIRIT) 2013
guidelines,14 reported using the Consolidated Standards of Re-
porting Trials (CONSORT) guidelines and according to the In-
ternational Conference on Harmonization E9 Statistical Prin-
ciples for Clinical Trials,15,16 and registered on ClinicalTrials.gov
(identifier NCT01038583).
Both ASPREE and ASPREE-D study methods are pub-
lished in detail elsewhere (protocol in Supplement 1).7,9 In Aus-
tralia, recruitment largely took place in primary care settings.
General practitioners provided a list of participants who were
potentially eligible, and they were sent letters of invitation.
When participants contacted the ASPREE Coordinating Cen-
ter, screening questions were asked, and further screening
was conducted at 2 baseline study visits. In between the study
visits, the general practitioners assessed participants’ health
and those considered sufficiently healthy for a primary pre-
vention trial of low-dose aspirin were deemed eligible for the
study. Researchers in the US identified participants using clinic-
based mailing lists, electronic medical records, and advertise-
ments. Men and women were included in the study if they were
willing and able to give informed consent and were eligible for
randomization. Key exclusion criteria were a history of a di-
agnosed cardiovascular event or established cardiovascular dis-
ease (including stroke, transient ischemic attack, myocardial
infarction, unstable angina, coronary artery reperfusion pro-
cedures and bypass grafting, abdominal aortic aneurysm, and
cardiac failure); atrial fibrillation; dementia or a score of less
than 78 on the Modified Mini-Mental State Examination; sub-
stantial physical disability, defined by severe difficulty or in-
ability to perform any of the 6 Katz activities of daily living at
baseline; a condition with a high current or recurrent risk of
bleeding; anemia; a condition likely to cause death within 5
years; current use of other antiplatelet or antithrombotic medi-
cation; current use of aspirin for secondary prevention; or un-
controlled hypertension (systolic blood pressure ≥180 mm Hg
and/or diastolic blood pressure ≥105 mm Hg).
Randomization of the study drug followed a block ran-
domization procedure and was stratified by site and age (65-79
vs >80 years). Participants were randomized to receive either
Key Points
Question Does low-dose aspirin reduce the risk of depression in
healthy older adults?
Findings In this randomized clinical trial of 19 114 older adults in
Australia and the United States, those taking low-dose aspirin (100
mg daily) did not have a lower rate of prevalent depression
compared with those taking a placebo, per measurements taken at
any of the postrandomization annual visits.
Meaning In this study, low-dose aspirin did not prevent
depression in healthy older adults.
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100 mg of enteric-coated aspirin or an enteric-coated pla-
cebo, which were identical in appearance, in a ratio of 1:1. Study
participants, investigators, and general practitioner coinves-
tigators were blinded to treatment allocation.
The ASPREE study began in March 2010, completed re-
cruitment in December 2014, and was concluded in June 2017
because of a National Institutes of Health determination of fu-
tility regarding the primary end point. The primary ASPREE
end point was a composite of death or dementia (adjudicated
according to the DSM-IV criteria) or persistent loss of the same
Katz basic activity of daily living. All clinical and safety end
points were adjudicated by independent end point adjudica-
tion committees who were provided with deidentified clini-
cal information about the event.
The principal outcome variable of ASPREE-D was a proxy
measure of major depressive disorder, defined as a CES-D-10
score of 8 or more. Because some participants may have had
a CES-D-10 score of 8 or more at baseline or a history of de-
pression, this primary outcome pooled both incident and re-
current depression. The CES-D-10 is a validated self-rated ques-
tionnaire with a single factor structure17 that indexes depressive
symptom severity in community populations.18,19 When com-
pared with a formal psychiatric diagnosis of late-life depres-
sion, the scale has been shown to have a sensitivity of 97% and
a specificity of 84%.20 Against a formal DSM-IV diagnosis, the
sensitivity and specificity of the CES-D-10 were 82% and 83%,
respectively.21
The CES-D-10 was initially administered at baseline and
at years 1, 3, 5, and 7. On receipt of further funding (National
Health and Medical Research Council identifier GNT1081901),
we added CES-D-10 assessments to years 2, 4, and 6. Partici-
pants were thus assessed for depression annually until the end
of their participation in the study. The number of partici-
pants who reached the CES-D-10 threshold at any annual fol-
low-up was a secondary outcome measure of ASPREE and a
primary outcome of ASPREE-D. The SF-12 was administered
annually. The mental component summary score was a sec-
ondary outcome measure of ASPREE-D.
The target ASPREE sample size was 19 000. To assess
power for the ASPREE-D primary hypothesis, we extrapo-
lated from the extant literature22 that the risk of prevalent
depression at any time in the placebo group would be 10%.
We anticipated a 5% annual dropout rate and a within-
participant correlation of 0.60 between baseline and fol-
low-up measurements of depression, using a compound
symmetry matrix. Based on these assumptions, we had 90%
power to detect the specified difference in depression risk (ie,
an odds ratio [OR] of 0.90 at annual follow-up) between the
aspirin and placebo group at a 5% significance level.7
Statistical Analyses
Primary analyses were undertaken by 3 authors (M.M., J.E.L.,
and R.W.) on an intent-to-treat basis, including all partici-
pants as randomized regardless of treatment received. De-
tails of the predefined statistical analyses plan for ASPREE have
been published elsewhere.8 The primary effectiveness analy-
sis compared the aspirin and the placebo groups with regard
to changes in the prevalence ratio of CES-D-10 scores of 8 or
more from baseline to annual follow-up visits. Treatment ef-
fects for the repeated binary CES-D-10 outcomes were deter-
mined via a population mean model using the generalized es-
timating equation (GEE) approach with logit link function. The
GEE model accounted for within-individual repeated mea-
sures using an exchangeable working correlation matrix, and
a robust sandwich variance estimator was used. The model con-
tained the fixed effect of intervention allocation and nominal
values of measurement points (annual visits) as the main ef-
fects, and a 2-way interaction between intervention alloca-
tion and annual visit. The 2-way interaction estimates the ef-
fect of aspirin across the annual visits in this setting. Ratios of
ORs and 95% CIs from the 2-way interaction parameters were
reported to compare the aspirin group with placebo at each an-
nual visit follow-up with respect to baseline. The global test
of the interaction term was then used to test the primary
hypothesis of differential between-group (ie, aspirin vs pla-
cebo) change in the proportions of CES-D-10 scores of 8 or more.
Similar analytical approaches were used for exploratory analy-
ses based on higher cutoffs of CES-D-10 scores at 10 or more
and 12 or more, given data that biological therapies, such as
antidepressants, may have greater efficacy in individuals with
more severe depression.23
The GEE models, assuming Gaussian distribution with
identity link function, were used for analyzing the SF-12
mental component. The GEE models accounted for within-
individual repeated measures using an unstructured work-
ing correlation matrix. The SF-12 models used the same fixed-
effect parameter structure as the CES-D-10 binary outcome
models, and for SF-12, the 2-way interaction of intervention
allocation and follow-up time estimated the intervention ef-
fect as between-group differential change from baseline scores
at each annual visit follow-up. The coefficients from the 2-way
interactions were reported as aspirin effects at each fol-
low-up annual visit, with 95% CIs. In addition, the Cohen d ef-
fect size for between-group differential change was reported.
Cox proportional-hazards models were used in participants
with CES-D-10 scores less than 8 at baseline to compare inci-
dence rate of CES-D-10 scores of 8 or more at annual follow-
ups between the aspirin and placebo groups. Hazard ratios and
95% CIs were reported.
Logistic regression was used for comparing overall pro-
portion of hospitalization at follow-up periods attributable to
depression in the aspirin and placebo groups. All tests of treat-
ment effects were conducted using an α level of .05. For the
primary outcome, P values were not presented for the annual
follow-up comparisons, and only the overall χ2 test for the in-
teraction was reported. Confidence intervals and P values were
not adjusted for multiple comparisons in secondary out-
comes. All analyses were performed using Stata version 15
(StataCorp).
Results
A total of 19 114 participants (16 703 in Australia and 2411 in the
US) were recruited from March 2010 to December 2014 and ran-
domized to receive aspirin or placebo (9525 participants to the
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aspirin group and 9589 to the placebo group) (Figure 1). The
demographic and clinical characteristics of the participants at
baseline according to the CES-D-10 cutoff in both groups
were similar (Table 1). The mean (SD) age of the participants
was 75.2 (4.60) years in the aspirin group and 75.1 (4.5) years
in the placebo group, and 9531 (56.4%) of the participants
were women. Regarding background, 16 007 participants
(93.5%) were white, and 16 463 (95.6%) spoke English at
home. Details of the baseline characteristics of the cohort are
published elsewhere.24
The mean (SD) CES-D-10 score at baseline was 3.2 (3.3) in
both groups. There were 1879 participants with a baseline CES-
D-10 score of 8 or more, with 925 (9.7%) in the aspirin group
and 954 (9.9%) in the placebo group. A total of 1666 partici-
pants (50.2% in the aspirin group) reported a history of de-
pression (ie, having ever been diagnosed or treated by a
physician for depression), of whom 202 (24.1%) had CES-D-
10 scores of 8 or more at baseline taking aspirin and 206 (24.9%)
taking placebo. Subgroup analysis of these participants showed
no significant difference in the prevalence of depressive symp-
toms at annual follow-ups (follow-up year by treatment group
interaction: χ26, 3.75; P = .71). Further exploration showed no
specific pattern in baseline adjusted depressive symptoms ra-
tios at annual follow-ups (OR range, 0.92-1.67). Antidepres-
sant use was not statistically different between treatment
groups at baseline or across annual follow-ups.
Adherence to treatment was measured, and 11 281 of 17 868
participants (63.1%) were still taking study medication after
the median 4.7 years of follow-up. The participants in each
group taking the study medication in the final year num-
bered 5512 of 8869 (62.1%) for aspirin and 5769 of 8999 (64.1%)
for placebo. When calculated as a proportion of time in the
study, participants in the aspirin arm took the study medica-
tion for a mean (SD) of 73% (35%) of their time in the study;
this was a mean (SD) of 75% (34%) in the placebo arm. These
rates are consistent with other pragmatic primary prevention
trials.
Principal End Point of ASPREE-D (CES-D)
Of 19 114 randomized participants, 1 participant had no CES-
D-10 measurement and 19 113 participants had a baseline and
at least 1 valid follow-up CES-D-10 measurement. In total,
79 886 CES-D-10 participant measurements were reported
across the study period, with a mean of 4.2 measurements per
participant.
Table 2 shows the number of participants with CES-D-
10 scores of 8 or more in aspirin and placebo groups at base-
line and follow-up annual visits. The prevalence of depres-
sive symptoms was higher at annual visits than baseline in both
groups (Table 2), with the proportion of participants with CES-
D-10 scores of 8 or more increasing to almost double at the end
of follow-up. However, the changes from baseline were not sig-
nificantly different between aspirin and placebo groups.
Secondary End Points of ASPREE-D
SF-12 Mental Scores
A total of 90 980 SF-12 measurements from 19 111 participants
were taken over the study period (Table 3). The mean (SD) men-
tal component summary scores at baseline were 55.8 (7.1) and
55.6 (7.2) in the aspirin and placebo groups, respectively. Be-
tween-group differential changes (aspirin vs placebo) from base-
line ranged from 0.0 to 0.3 points in favor of the placebo group;
however, the differences were very small (Cohen d ≤0.10). No
significant differences were observed between aspirin and pla-
cebo groups in differential changes from baseline of the SF-12
mental component summary score (χ26, 9.61; P = .14).
Hospitalization Attributable to Depression
A total of 58 participants were hospitalized for depression dur-
ing the study period, of whom 33 (0.35%) were in the aspirin
group and 25 (0.26%) were in the placebo group. There was
Figure 1. Consolidated Standards of Reporting Trials Diagram for the
Aspirin for the Prevention of Depression Trial
83 376
60 213 Ineligible or unwilling
4049 Ineligible or unwilling
23 163 Screened at baseline
19 114 Randomized
9525 Assigned to aspirin
1 Had no CES-D-10 score










9524 Had valid CES-D-10 
scores at baseline
9589 Included
9586 Had valid CES-D-10 
scores at baseline
9006 Had valid CES-D-10 scores
at year 1
9094 Had valid CES-D-10 scores
at year 1
3535 Had valid CES-D-10 scores
at year 2
3601 Had valid CES-D-10 scores
at year 2
7550 Had valid CES-D-10 scores
at year 3
7620 Had valid CES-D-10 scores
at year 3
5137 Had valid CES-D-10 scores
at year 4
5272 Had valid CES-D-10 scores
at year 4
3594 Had valid CES-D-10 scores
at year 5
3663 Had valid CES-D-10 scores
at year 5
1351 Had valid CES-D-10 scores
at year 6
1357 Had valid CES-D-10 scores
at year 6
Screened by telephone
CES-D-10 indicates Center for Epidemiologic Studies Depression 10-item scale.
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Effect of Aspirin on the Prevention of Depression In Older People 
Table 1. Demographic Characteristics of Participants, Stratified by Center for Epidemiologic Studies 
Depression 1O-ltem Scale (CES-O-1O) Score of 8 or More at Baseline 
Patients, No. (%) 
Aspirin group (n = 9524)> Placebo group (n = 9586)> 
Demographic categories CES-D-10 < 8 CES-D-10 ~ 8 CES-D-10 < 8 CES-D-10 ~ 8 
Total 8599 (90.3) 925 (9.7) 8632 (90.0) 954 (10.0) 
Age, mean (SD), y 75.1 (4.6) 75.3 (4.8) 75.1 (4.5) 75.1 (4.6) 
Weight, mean (SD), kg 76.9 (15.0) 77.6 (16.6) 77.1 (14.7) 76.6 (15.8) 
BMI, mean (SD) 28.0(4.7) 28.8 (5.5) 28.0 (4.6) 28.6 (5.3) 
Female 4778 (55.6) 595 (64.3) 4753 (55.1) 653 (68.5) 
Country 
Australia 7526 (87.5) 795 (86.0) 7578 (87.8) 800 (83.9) 
United States 1073 (12.5) 130 (14.0) 1054 (12.2) 154 (16.1) 
Living status 
At home alone 2710 (31.5) 387 (41.8) 2739 (31.7) 414 (43.4) 
At home with family, 5858 (68.1) 529 (57.2) 5856 (67.8) 534 (56.0) 
friends, or a spouse 
In a residential home• 31 (0.4) 9(1.0) 37 (0.5) 6 (0.6) 
Hispanic/Latino ethnicity 215 (2.5) 25 (2.7) 209 (2.4) 39 (4.1) 
Race 
White 7992 (94.0) 832 (90.6) 8015 (93.8) 855 (90.7) 
Black/African American 391 (4.6) 66 (7.2) 387 (4.5) 65 (6.9) 
Other 124 (1.4) 20 (2.2) 143 (1.7) 23 (2.4) 
English-speaking 8189 (95.2) 885 (95.7) 8274 (95.9) 912 (95.6) 
Born overseas 1928 (22.4) 215 (23.2) 1937 (22.4) 195 (20.4) 
Education > 12 y 4744 (55.2) 473 (51.2) 4737 (54.9) 523 (54.8) 
Smoking status 
Current 298 (3.5) 54 (5.8) 326 (3.8) 56 (5.9) 
Former 3519 (40.9) 389 (42.1) 3522 (40.8) 367 (38.4) 
Never 4782 (55.6) 482 (52.1) 4784 (55.4) 531 (55.7) 
Alcohol drinking 
Current 6644 (77.3) 664 (71.8) 6629 (76.8) 701 (73.5) 
Former 488 (5.7) 78 (8.4) 493 (5.7) 77 (8.1) 
Never 1467 (17.0) 183 (19.8) 1510 (17.5) 176 (18.4) 
Depression history' 
unsure 48 (1.6) 8(1.8) 41 (1.4) 12 (2.8) 
No 2356 (77.5) 238 (53.1) 2385 (78.2) 216 (49.8) 
Yes 635 (20.9) 202 (45.1) 623 (20.4) 206 (47.4) 
Original Investigation Research 
Abbreviation, BMI, body mass index 
(calculated as weight in kilograms 
divided by height in meters squared). 
• One CES-D-1O score was missing in 
the aspirin group, and 3 were 
missing in the placebo group at 
baseline. 
•supervised care or assisted living. 
' The question about a history of 
depression were only asked after 
June 2013 (n = 6970 participants). 
no statistically significant difference in the between-group 
comparison of hospitalization proportions (OR, 1.33 [95% CI, 
0.79-2.24]). 
cutoffs oflO or more and 12 or more, as was seen for the cutoff 
score of8 or more (eTable in Supplement 2). None of these were 
statistically significant. 
Incidence Rate of CES-O-1O Scores of 8 or More 
A total of 2350 participants in the aspirin group (70.4 events 
per 1000 person-years) and 2314 in the placebo group (69.1 
events per 1000 person-years) reached the end point of a 
CES-D-1O score of 8 or more for the first time at an annual 
follow-up. The between-group difference was not significant 
(hazard ratio, 1.02 [95% CI, 0.96-1.08]; P = .54) (Figure 2). 
Exploratory End Point of ASPREE-D 
CES-O-1O Scores oflO or More and 12 or More 
In a sensitivity analysis, a similar pattern of only small differ-
ences between the aspirin and placebo groups was observed for 
those with more severe depression using both CES-D-10 score 
Discussion 
The results of ASPREE-D failed to support the primary hypoth-
esis of this study that individuals taking low-dose aspirin would 
have a lower rate of prevalent depression compared with those 
taking placebo, with depression defined in this large prag-
matic trial as a CES-D-10 score of 8 or more at any postran-
domization annual visit. Given the large sample size, the pro-
longed observation window, and the rigor of the primary 
AS PREE study in ascertaining end points and maintaining fol-
low-up, this suggests that low-dose aspirin is unlikely to beef-
fective in preventing depression in a healthy older cohort. It 
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also adds to the null findings for aspirin in cardiovascular
events,25 disability-free survival,26 and all-cause mortality27
in the ASPREE parent study.
The association of depression with elevated markers of in-
flammation has spurred the initiation of multiple preclinical,28-30
epidemiological,31-34 and clinical35,36 studies of aspirin and other
anti-inflammatory therapies, such as celecoxib. A meta-analysis
of observational data supports the efficacy of celecoxib in
depression.37 Aspirin is a nonsteroidal anti-inflammatory agent
that acts as an irreversible inhibitor of both cyclooxygenase-1 and
cyclooxygenase-2. It promotes production of anti-inflammatory
moieties, such as lipoxins, which may lower levels of inflamma-
torybiomarkers, includingC-reactiveprotein,tumornecrosisfac-
tor α, and IL-6, and reduce biomarkers of oxidative damage.6
Aspirin was associated with increased sucrose preference
and reduced immobility in the forced swim test, as well as de-
creased cortisol levels and increased brain serotonin levels in
an interferon model of depression in Sprague Dawley rats,
suggesting both clinical model efficacy and influences on sa-
lient pathways.38 Several pharmacoepidemiology studies
suggest that people taking aspirin may have a lower risk for
depression,33,34,39,40 notwithstanding some conflicting data that
have failed to show a benefit of aspirin.41,42 Early clinical trials
of aspirin in mood disorders have also generated promising but
preliminary signals of efficacy. Adjunctive aspirin together with
sertraline was superior to sertraline alone in participants with
major depressive disorder. Additionally, in two 2 × 2 designs of
minocycline and aspirin and N-acetylcysteine and aspirin, both
combination strategies seemed more effective than the placebo
combinations.31,43,44 However, treatment and prevention stud-
ies of definitive methodological quality are necessary to confirm
these preliminary findings.
The major successes in morbidity of other noncommuni-
cable disorders have arguably been in prevention, not treat-
ment. Unlike the declining rates of disability resulting from, for
example, cardiovascular disease,45 the burden of disability from
depression has not declined and may even be increasing.46 The
identification of inflammatory biomarkers associated with de-
pression risk suggests that strategies targeting these may be a
plausible therapeutic and preventive approach. Because these
inflammatory markers are shared between a myriad of com-
mon noncommunicable medical disorders, treatment affect-
ing these pathways may provide compound benefits across sev-
eral common mental and medical conditions.47 This argues for
a shared approach to tackle noncommunicable disorders,48 a
Table 2. Comparison of Prevalent Scores of 8 or More on the Center for Epidemiologic Studies
Depression 10-Item Scale at Follow-up in Aspirin and Placebo Groupsa
Year Patients, No. Aspirin group, No. (%) Placebo group, No. (%) Odds ratiob (95% CI)
Baseline 19 110 925 (9.7) 954 (9.9) NA
1 18 100 1454 (16.1) 1424 (15.7) 1.06 (0.96-1.18)
2 7132 566 (16.0) 539 (15.0) 1.09 (0.94-1.24)
3 15 170 1316 (17.4) 1307 (17.1) 1.06 (0.95-1.17)
4 10 409 868 (16.9) 903 (17.1) 1.04 (0.92-1.17)
5 7257 663 (18.5) 675 (18.4) 1.05 (0.92-1.19)
6 2708 257 (19.0) 245 (18.1) 1.13 (0.94-1.34)
Abbreviation: NA, not applicable.
a P value and (test statistic) for
intervention by follow-up (annual
visit) interaction test:
χ 26, 2.68; P = .85.
b Odds ratio comparing aspirin with
placebo at follow-up annual visit,
divided by the odds ratio comparing
the 2 groups at baseline.
Table 3. Twelve-Item Short-Form Health Survey Mental Component Summary Scores Comparison







(Cohen d)Aspirin group Placebo group
Baseline 19 106 55.8 (7.1) 55.6 (7.2) NA NA
1 18 088 55.5 (7.4) 55.6 (7.1) –0.3 (–0.5 to 0.0) –0.03
2 17 350 55.7 (7.3) 55.6 (7.4) 0.0 (–0.2 to 0.2) 0.00
3 15 112 55.6 (7.5) 55.6 (7.3) –0.1 (–0.4 to 0.1) –0.01
4 11 413 55.6 (7.5) 55.7 (7.4) –0.2 (–0.5 to 0.0) –0.02
5 7209 55.2 (7.5) 55.4 (7.5) –0.3 (–0.7 to 0.0) –0.04
6 7209 55.5 (7.6) 55.4 (7.2) –0.2 (–0.7 to 0.2) –0.07
Abbreviation: NA, not applicable.
a Differential change from baseline at
follow-ups (aspirin vs placebo) was
estimated from a 2-way interaction
of intervention allocation and
follow-up annual visit from a
generalized estimating equation
model; the references were the
baseline measurement and the
placebo group.
b P value and test statistic for
intervention by follow-up annual
visit interaction test:
χ 26, 9.61; P = .14.

























60 1 2 3 4 5
Aspirin
Placebo
An episode of major depressive disorder was defined as Center for
Epidemiologic Studies Depression 10-item scale score of 8 or more. Shown is
the cumulative incidence of incident depression (ie, first episodes of depression
among those in whom it was not present at baseline) observed during the trial.
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key philosophical premise of ASPREE. However, the many off-
target outcomes of aspirin use,49 particularly those associated
with bleeding,25 might challenge the widespread indication of
aspirin for primary prevention in an older population that is oth-
erwise healthy. Accordingly, the significant increased risk of
bleeding events documented in the ASPREE study was not
matched by benefit in terms of reduced depression risk.
Strengths of the study include its large sample size, ex-
tensive characterization of the participants, the extensive
length of the follow-up period, the participation of healthy
older people across 2 continents, and the simplicity of the
design. In this complex multi–end point study, structured
diagnostic interviews were not feasible. The CES-D-10
score, despite being designed as a screening tool, is vali-
dated for use in such studies, correlates well with structured
interview, and obviates interrater variability issues in multi-
site studies.
Limitations
The fact that the ASPREE cohort had higher baseline quality
of life than is noted in other population-based studies of older
adults probably suggests biased recruitment in favor of indi-
viduals who are healthy, a reflection of this primary preven-
tion study’s exclusion criteria. Therefore, some demographic
features may have differed from the broader population (such
as lower rates of smoking), which may compromise assay
sensitivity and the generalizability of our findings.50 Never-
theless, there were high CES-D-10 scores at baseline across the
cohort, despite the selection of an older population that was
relatively healthy. These data are thus not necessarily trans-
latable to people with substantial medical comorbidities or
younger populations. Annual assessments may miss intercur-
rent changes in mood.
The dosage of aspirin is an area of uncertainty. The litera-
ture is unclear on the question of whether low-dose aspirin
is able to lower inflammatory cytokines to a meaningful
extent.51-53 A successful treatment study of aspirin in schizo-
phrenia used a dose of 1 g daily.54 This negative trial therefore
should not necessarily inhibit future studies that, for ex-
ample, include younger cohorts at earlier illness stages, use
higher doses, stratify for baseline biomarkers, or examine
groups at high risk and explore indicated or secondary pre-
vention. Stratification according to baseline biomarkers might
clarify groups that could benefit from such therapies; future
studies in this regard are planned. Future studies should also
consider the balance between potential benefits vs harms of
low-dose aspirin for primary prevention—especially in light of
the significant increased bleeding risk described in ASPREE and
other cohorts, including in younger individuals.55,56
Conclusions
In summary, this study failed to confirm any potential ben-
efit of low-dose aspirin in reducing the risk of depression in
this relatively healthy older population. This lack of efficacy
is compounded by a clear increase in the risk of bleeding events
documented in previous reports from this study.24 The find-
ings do not support the hypothesis that low-dose aspirin can
prevent late-life depression.
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